Rimegepant sulfate

硫酸瑞美吉泮

Report date: 2026/05/12 20:00:17
NME

Base Information

Drug NameRimegepant sulfate
Drug Alias NameRimegepant利美戈潘Rimegepantum瑞美吉泮Rimegepant Zydis® ODT +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCalcitonin gene-related peptide receptor antagonists
TargetsCalcitonin gene-related peptide receptor
Therapy Area/IndicationsPsoriasisParoxysmal HemicraniaMigraine Disorders +[6] 
Global Approved IndicationsMigraine Disorders
Approved Indications in ChinaMigraine Disorders
Original Approved Country/TerritoryUnited States
Original Approved Date2020/02/27
Country/TerritoryCzechiaCanadaUnited States +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesPatheon Biologics LlcCatalent Pharma Solutions LtdBioshin Hong Kong Ltd +[14] 
Inactive CompaniesN/A
Active IndicationsPsoriasisParoxysmal HemicraniaMigraine Disorders +[4] 
Inactive IndicationsTrigeminal NeuralgiaTemporomandibular Joint Dysfunction Syndrome

Other Information

ATC CodeN02C
Related LinksWikipediaDrugBankKEGG